Janssen Biotech Drug Patent Portfolio
Janssen Biotech owns 5 orange book drugs protected by 38 US patents with Zytiga having the least patent protection, holding only 2 patents. And Erleada with maximum patent protection, holding 11 patents. Given below is the list of Janssen Biotech's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11850248 | Therapies with 3rd generation EGFR tyrosine kinase inhibitors | 01 Aug, 2041 | Active |
| US12138351 | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof | 13 Apr, 2041 | Active |
| US11879013 | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors | 21 May, 2040 | Active |
| US11963952 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer | 30 Jan, 2040 | Active |
| US10702508 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer | 30 Apr, 2038 | Active |
| US11453656 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | 18 Apr, 2038 | Active |
| US11981659 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | 18 Apr, 2038 | Active |
| US11091459 | Niraparib compositions | 27 Mar, 2038 | Active |
| US11673877 | Niraparib compositions | 27 Mar, 2038 | Active |
| US11077106 | Cancer treatment | 02 Feb, 2038 | Active |
| US11207311 | Method of treating prostate cancer | 28 Jul, 2037 | Active |
| US11986468 | Methods of treating prostate cancer | 28 Jul, 2037 | Active |
| US11986469 | Methods of treating prostate cancer | 28 Jul, 2037 | Active |
| US11992486 | Methods of treating prostate cancer | 28 Jul, 2037 | Active |
| US10478494 | FGFR/PD-1 combination therapy for the treatment of cancer | 13 Aug, 2036 | Active |
| US10898482 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | 09 Feb, 2036 | Active |
| US11684620 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | 09 Feb, 2036 | Active |
| US12037644 | Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor | 18 Oct, 2035 | Active |
| US9593098 | Compounds and compositions for modulating EGFR mutant kinase activities | 13 Oct, 2035 | Active |
| US9902714 | Quinoxaline derivatives useful as FGFR kinase modulators | 26 Mar, 2035 | Active |
| US10052314 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | 23 Sep, 2033 | Active |
| US10849888 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | 23 Sep, 2033 | Active |
| US9884054 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | 23 Sep, 2033 | Active |
| USRE49353 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | 23 Sep, 2033 | Active |
| US9481663 | Crystalline forms of an androgen receptor modulator | 04 Jun, 2033 | Active |
| US8895601 | Pyrazolyl quinoxaline kinase inhibitors | 12 Apr, 2033 | Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | 04 Aug, 2031 | Active |
| US9464071 | Pyrazolyl quinoxaline kinase inhibitors | 28 Apr, 2031 | Active |
| US8071623 | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors | 27 Mar, 2031 | Active |
| US8445507 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | 15 Sep, 2030 | Active |
| US8436185 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | 24 Apr, 2029 | Active |
| US8822438 | Methods and compositions for treating cancer | 24 Aug, 2027 | Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer | 12 Aug, 2027 | Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer | 12 Aug, 2027 | Active |
| US8802689 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | 27 Mar, 2027 | Active |
| US9388159 | Substituted diazaspiroalkanes as androgen receptor modulators | 27 Mar, 2027 | Active |
| US9987261 | Substituted diazaspiroalkanes as androgen receptor modulators | 27 Mar, 2027 | Active |
| US5604213 | 17-substituted steroids useful in cancer treatment | 18 Feb, 2014 | Expired |
Latest Legal Activities on Janssen Biotech's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Janssen Biotech.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 09 Jul, 2024 | US10898482 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849888 |
| Recordation of Patent eCertificate of Correction | 30 Apr, 2024 | US10702508 |
| Mail Patent eCofC Notification | 30 Apr, 2024 | US10702508 |
|
Email Notification
Critical
| 30 Apr, 2024 | US10702508 |
| Patent eCofC Notification | 30 Apr, 2024 | US10702508 |
|
Recordation of Patent Grant Mailed
Critical
| 23 Apr, 2024 | US11963952 |
|
Email Notification
Critical
| 23 Apr, 2024 | US11963952 |
| Recordation of Patent eGrant | 23 Apr, 2024 | US11963952 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 23 Apr, 2024 | US11963952 |
| Mail Patent eGrant Notification | 23 Apr, 2024 | US11963952 |
| Patent eGrant Notification | 23 Apr, 2024 | US11963952 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Apr, 2024 | US9481663 |
|
Email Notification
Critical
| 04 Apr, 2024 | US11963952 |
|
Issue Notification Mailed
Critical
| 03 Apr, 2024 | US11963952 |
Janssen Biotech's Drug Patent Litigations
Janssen Biotech's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 11, 2011, against patent number US8859562. The petitioner , challenged the validity of this patent, with Thomas Helleday as the respondent. Click below to track the latest information on how companies are challenging Janssen Biotech's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8822438 | December, 2015 |
FWD Entered
(17 Jan, 2018)
| Janssen Oncology, Inc. | Amerigen Pharmaceuticals, Ltd. |
| US8822438 | June, 2016 |
FWD Entered
(17 Jan, 2018)
| Janssen Oncology, Inc. | Argentum Pharmaceuticals LLC |
| US8822438 | June, 2016 |
FWD Entered
(17 Jan, 2018)
| Janssen Oncology, Inc. | Mylan Pharmaceuticals Inc. |
| US8822438 | August, 2016 |
FWD Entered
(17 Jan, 2018)
| Janssen Oncology, Inc. | Wockhardt Bio AG |
| US8822438 | February, 2017 |
FWD Entered
(17 Jan, 2018)
| Janssen Oncology, Inc. | ACTAVIS LABORATORIES FL, INC. |
| US8859562 | October, 2011 |
Decision
(25 Mar, 2014)
| Thomas Helleday | |
Janssen Biotech Drug Patents' Oppositions Filed in EPO
Janssen Biotech drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 13, 2012, by Strawman Limited. This opposition was filed on patent number EP04743564A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP19169275A | Feb, 2022 | Generics [UK] Limited | Granted and Under Opposition |
| EP17187458A | Jun, 2021 | Sandoz AG | Granted and Under Opposition |
| EP17187458A | Jun, 2021 | Synthon BV | Granted and Under Opposition |
| EP17187458A | Jun, 2021 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP18157435A | Apr, 2021 | SANDOZ AG | Granted and Under Opposition |
| EP18157435A | Apr, 2021 | Sagittarius Intellectual Property Consultants Ltd | Granted and Under Opposition |
| EP13800681A | Jan, 2019 | Luigi, Rumi | Granted and Under Opposition |
| EP13800681A | Jan, 2019 | Sagittarius Intellectual Property LLP | Granted and Under Opposition |
| EP13800681A | Jan, 2019 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP04798705A | May, 2012 | Adams, Harvey Vaughan John | Opposition procedure closed |
| EP04798705A | May, 2012 | STRAWMAN LIMITED | Opposition procedure closed |
| EP04743564A | Apr, 2012 | Adams, Harvey Vaughan John | Patent maintained as amended |
| EP04743564A | Apr, 2012 | STRAWMAN LIMITED | Patent maintained as amended |
Janssen Biotech's Family Patents
Janssen Biotech drugs have patent protection in a total of 57 countries. It's US patent count contributes only to 13.7% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Janssen Biotech Drug List
Given below is the complete list of Janssen Biotech's drugs and the patents protecting them.
1. Akeega
Akeega is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11091459 | Niraparib compositions |
27 Mar, 2038
(12 years from now)
| Active |
| US11673877 | Niraparib compositions |
27 Mar, 2038
(12 years from now)
| Active |
| US11207311 | Method of treating prostate cancer |
28 Jul, 2037
(12 years from now)
| Active |
| US11986468 | Methods of treating prostate cancer |
28 Jul, 2037
(12 years from now)
| Active |
| US11986469 | Methods of treating prostate cancer |
28 Jul, 2037
(12 years from now)
| Active |
| US11992486 | Methods of treating prostate cancer |
28 Jul, 2037
(12 years from now)
| Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
04 Aug, 2031
(6 years from now)
| Active |
| US8071623 | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
27 Mar, 2031
(5 years from now)
| Active |
| US8436185 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
24 Apr, 2029
(3 years from now)
| Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer |
12 Aug, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Akeega's drug page
2. Balversa
Balversa is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11077106 | Cancer treatment |
02 Feb, 2038
(12 years from now)
| Active |
| US10478494 | FGFR/PD-1 combination therapy for the treatment of cancer |
13 Aug, 2036
(11 years from now)
| Active |
| US10898482 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
09 Feb, 2036
(10 years from now)
| Active |
| US11684620 | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
09 Feb, 2036
(10 years from now)
| Active |
| US12037644 | Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor |
18 Oct, 2035
(10 years from now)
| Active |
| US9902714 | Quinoxaline derivatives useful as FGFR kinase modulators |
26 Mar, 2035
(9 years from now)
| Active |
| US8895601 | Pyrazolyl quinoxaline kinase inhibitors |
12 Apr, 2033
(7 years from now)
| Active |
| US9464071 | Pyrazolyl quinoxaline kinase inhibitors |
28 Apr, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Balversa's drug page
3. Erleada
Erleada is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11963952 | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
30 Jan, 2040
(14 years from now)
| Active |
| US10702508 | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
30 Apr, 2038
(12 years from now)
| Active |
| US10052314 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
23 Sep, 2033
(8 years from now)
| Active |
| US10849888 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
23 Sep, 2033
(8 years from now)
| Active |
| US9884054 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
23 Sep, 2033
(8 years from now)
| Active |
| USRE49353 | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
23 Sep, 2033
(8 years from now)
| Active |
| US9481663 | Crystalline forms of an androgen receptor modulator |
04 Jun, 2033
(7 years from now)
| Active |
| US8445507 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
15 Sep, 2030
(5 years from now)
| Active |
| US8802689 | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
27 Mar, 2027
(1 year, 8 months from now)
| Active |
| US9388159 | Substituted diazaspiroalkanes as androgen receptor modulators |
27 Mar, 2027
(1 year, 8 months from now)
| Active |
| US9987261 | Substituted diazaspiroalkanes as androgen receptor modulators |
27 Mar, 2027
(1 year, 8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Erleada's drug page
4. Lazcluze
Lazcluze is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11850248 | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
01 Aug, 2041
(16 years from now)
| Active |
| US12138351 | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
13 Apr, 2041
(15 years from now)
| Active |
| US11879013 | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
21 May, 2040
(14 years from now)
| Active |
| US11453656 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
18 Apr, 2038
(12 years from now)
| Active |
| US11981659 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
18 Apr, 2038
(12 years from now)
| Active |
| US9593098 | Compounds and compositions for modulating EGFR mutant kinase activities |
13 Oct, 2035
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lazcluze's drug page
5. Zytiga
Zytiga is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8822438 | Methods and compositions for treating cancer |
24 Aug, 2027
(2 years from now)
| Active |
| US5604213 | 17-substituted steroids useful in cancer treatment |
18 Feb, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zytiga's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List